Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Other Receivables
Apontis Pharma AG
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Other Receivables
€357.9k
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Other Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Other Receivables
€3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Merck KGaA
XETRA:MRK
|
Other Receivables
€512m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
6%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Other Receivables
€1.5m
|
CAGR 3-Years
62%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Other Receivables
€494k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Other Receivables?
Other Receivables
357.9k
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Other Receivables amounts to 357.9k EUR.
What is Apontis Pharma AG's Other Receivables growth rate?
Other Receivables CAGR 3Y
14%
Over the last year, the Other Receivables growth was 322%. The average annual Other Receivables growth rates for Apontis Pharma AG have been 14% over the past three years .
You don't have any saved screeners yet